metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
la/mBC - HR-positive - 2nd line (L2) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2)
versus fulvestrant
	alpelisib plus fulvestrant vs. fulvestrant	2	statistically conclusive 28 % decrease in progression or deaths (PFS)	inconclusive results for: deaths (OS)	suggested 93 % increase in CBR but the degree if certainty is unassessable suggested 2.5-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
	buparlisib plus fulvestrant vs. fulvestrant	1	none	-	statistically conclusive 33 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 3.8-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
la/mBC - HR positive - L2 - all population breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - all population
versus fulvestrant
	buparlisib plus fulvestrant vs. fulvestrant	1	none	inconclusive results for: deaths (OS)	statistically conclusive 22 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 60 % increase in objective responses (ORR) but the degree if certainty is unassessable	-
la/mBC - HR positive - L2 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 2nd line (L2) la/mBC - HR positive - L2 - PIK3CA mutant
versus fulvestrant
	buparlisib plus fulvestrant vs. fulvestrant	1	none	inconclusive results for: objective responses (ORR)	suggested 24 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-